CSTL Castle Biosciences

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 employees.

"Winning a fourth Top Workplaces USA Award is a testament to our exceptional Castle team and people-first culture," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We are committed to fostering an environment where employees feel valued, supported and empowered to drive innovation, and this recognition reflects their passion and dedication to making a meaningful impact on patient care."

More than 42,000 organizations were invited to participate in the Top Workplaces USA survey. Winners of the Top Workplaces USA list were chosen solely on employee feedback gathered through a third-party administered by Energage. Results were calculated by comparing the survey’s research-based statements, including 15 culture drivers that are indicative of high performance against industry benchmarks. Castle’s survey participation rate of 95% and employee engagement score of 85% were both above the benchmark averages of 56% and 74%, respectively, for other similar healthcare companies participating in the Top Workplaces USA program.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be proud of. In today's market, leaders must ensure they’re allowing employees to have a voice and be heard. That's paramount. Top Workplaces do this, and it pays dividends.”

The comprehensive list of 2025 Top Workplaces USA can be found on and .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit  and connect with us on , ,  and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

About Energage

Making the world a better place to worktogether.™

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 19 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or .

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall

Source: Castle Biosciences Inc.



EN
07/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth ...

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 employees....

 PRESS RELEASE

Publication of Data from Prospective, Multicenter Study Demonstrates P...

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression1,2 A...

 PRESS RELEASE

Castle Biosciences to Present New Data at EADO Supporting the Clinical...

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle...

 PRESS RELEASE

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NC...

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle w...

 PRESS RELEASE

New Data to be Presented at the 2025 American Academy of Dermatology (...

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting, taking place March 7-11 in Orlando, Florida. “At Castle, we are dedicated to empowering clinicians with the insights needed to make more informed decisions in the management of skin cancers,” said Rebecca Critchley-Thorne, Ph.D., vice-president, research and development, of Castle Biosciences. “We remain co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch